This Drug Could End H.I.V. Why Hasn’t It?
The Daily

This Drug Could End H.I.V. Why Hasn’t It?

Jun 5, 2019
27:17
-(0)

About this episode

Dr. Robert Grant developed a treatment — a daily pill known as pre-exposure prophylaxis, or PrEP — that could stop the AIDS crisis. We look at why that hasn’t happened. Guests: Dr. Grant, who has been working on H.I.V. treatment and prevention for over 30 years, and Donald G. McNeil Jr., a science and health reporter for The New York Times. For more information on today’s episode, visit nytimes.com/thedaily. Background reading: Gilead Sciences, the maker of Truvada, the only drug approved to prevent H.I.V. infection, will donate enough of the drug to supply 200,000 patients, but critics questioned the company’s motives.The high cost of drugs remains a major obstacle to ending the AIDS epidemic.Here’s more information about PrEP from the Centers for Disease Control and Prevention website.

Comments

Rate this episode

Episode Details

Author
The New York Times
Show Type
full
Audio Format
audio/mpeg

We use analytics

We use Umami, a privacy-friendly analytics tool, to understand how visitors use this site. No personal data is collected and no data leaves our EU servers. You can accept or decline below. Privacy Policy